

31 Jan 2019 | Analysis

Device Week, Jan. 31, 2019 – Livongo's Acquisition Of myStrength; FDA Evaluates Peripheral Paclitaxel Devices Study

by Reed Miller

In this edition of Device Week, *Medtech Insight*'s Catherine Longworth chats with Marion Webb about Livongo's acquisition of behavioral health company myStrength and with Reed Miller about the controversy surrounding the meta-analysis finding of a higher mortality risk with paclitaxel-eluting peripheral devices.

Listen to the podcast via the player below:

Click here to explore this interactive content online

Medtech Insight articles addressing topics discussed in this episode: